Article information
Full text is only aviable in PDF
References
[1]
E.M. Mortensen, C. Coley, D.E. Singer, T.J. Marrie, D.S. Obrosky, W.N. Kapoor, et al.
Causes of death for patients with community-acquired pneumonia: results from the pneumonia patient outcomes research team cohort study.
Arch Intern Med, 162 (2002), pp. 1059-1064
[2]
R. Menéndez, A. Torres, J. Aspa, A. Capelastegui, C. Prat, F. Rodríguez de Castro.
Neumonía adquirida en la comunidad Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR).
Arch Bronconeumol, 46 (2010), pp. 543-558
[3]
J. Solé, A. Marcos, J. Aspa, F. Rodríguez de Castro.
Corticosteroids and communityacquired pneumonia.
Clin Pulm Med, 10 (2003), pp. 255-262
[4]
J.A. Kellum, L. Kong, M.P. Fink, L.A. Weissfeld, D.M. Yealy, M.R. Pinsky, et al.
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GENIMS) Study.
Arch Intern Med, 167 (2007), pp. 1655-1663
[5]
M. Christ-Crain, D. Stolz, S. Jutla, O. Couppis, C. Müller, R. Bingisser, et al.
Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia.
Am J Respir Crit Care Med, 176 (2007), pp. 913-920
[6]
S. Gotoh, N. Nishimura, O. Takahashi, H. Shiratsuka, H. Horinouchi, H. Ono, et al.
Adrenal function in patients with community-acquired pneumonia.
Eur Respir J, 31 (2008), pp. 1268-1273
[7]
M. Kolditz, M. Halank, B. Schulte-Hubbert, G. Höffken.
Adrenal function is related to prognosis in moderate community-acquired pneumonia.
Eur Respir J, 36 (2010), pp. 615-621
[8]
D. Annane, G. Meduri, P. Marik.
Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future!.
Eur Respir J, 31 (2008), pp. 1150-1152
[9]
M. Briel, H.C. Bucher, R. Boscacci, H. Furrer.
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection.
Cochrane Database Syst Rev, 3 (2006), pp. CD006150
[10]
N. Adhami, Y. Arabi, A. Raees, A. Al-Shimemeri, M. Ur-Rahman, Z.A. Memish.
Effect of corticosteroids on adult varicella pneumonia: cohort study and literature review.
Respirology, 11 (2006), pp. 437-441
[11]
R.C. Cheng, X.P. Tang, S.Y. Tan, B.L. Liang, Z.Y. Wan, J.Q. Fang, et al.
Treatment of Severe Acute Respiratory Syndrome with glucoesteroids he Guangzhou experience.
Chest, 129 (2006), pp. 1441-1452
[12]
M. Goldman, P.C. Johnson, G.A. Sarosi.
Fungal pneumonias: the endemic mycoses.
Clin Chest Med, 20 (1999), pp. 507-519
[13]
T. Lahm, S. Neese, A.T. Thornburg, M.D. Ober, G.A. Sarosi, C.A. Hage.
Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature.
Chest, 133 (2008), pp. 1478-1480
[14]
H.N. Wagner, I.L. Bennet, L. Lasagna, L.E. Cluff, M.B. Rosenthal, G.S. Mirick.
The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin.
Bull Johns Hopkins Hosp, 98 (1956), pp. 197-215
[15]
P. Marik, P. Kraus, J. Sribante, I. Havlik, J. Lipman, D.W. Johnson.
Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study.
Chest, 104 (1993), pp. 389-492
[16]
C. Montón, S. Ewig, A. Torres, M. El-Ebiary, X. Fililla, A. Rañó, et al.
Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study.
Eur Respir J, 14 (1999), pp. 218-220
[17]
M. Confalonieri, R. Urbino, A. Potena, M. Piatella, P. Parigi, G. Puccio, et al.
Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.
Am J Respir Crit Care Med, 171 (2005), pp. 242-248
[18]
M. Confalonieri, A. Potena, G. Carbone, R.D. Porta, E.A. Tolley, G.U. Meduri.
Acute respiratory failure in patients with severe community-acquired pneumonia. A prospective randomized evaluation of noninvasive ventilation.
Am J Respir Crit Care Med, 160 (1999), pp. 1585-1591
[19]
M. Mikami, M. Suzuki, H. Kitagawa, M. Kawakami, N. Hirota, H. Yamaguchi, et al.
Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization.
Lung, 185 (2007), pp. 249-255
[20]
C. García-Vidal, E. Calbo, V. Pascual, C. Ferrer, S. Quintana, J. Garau.
Effects of systemic steroids in patients with severe community-acquired pneumonia.
Eur Respir J, 30 (2007), pp. 951-956
[21]
C.L. Sprung, D. Annane, D. Keh, R. Moreno, M. Singer, K. Freivogel, et al.
Hydrocortisone therapy for patients with septic shock.
N Engl J Med, 358 (2008), pp. 111-124
[22]
J.I. Salluh, F.A. Bozza, M. Soares, J.C. Verdeal, H.C. Castro-Faria-Neto, J.R. Lapa e Silva, et al.
Adrenal response in severe community-acquired pneumonia: impact on outcomes and disease severity.
Chest, 134 (2008), pp. 947-954
[23]
D. Snijders, J. Daniels, C. De Graaf, T.S. Van der Werf, W.G. Boersma.
Efficacy of corticosteroids in community-acquired pneumonia. A randomized double-blinded clinical trial.
Am J Respir Crit Care Med, 181 (2010), pp. 975-982
[24]
G.U. Meduri, W.A. Bell, M. Confalonieri.
Glucocorticoid treatment in communityacquired pneumonia without severe sepsis No evidence of efficacy.
Am J Respir Crit Care Med, 181 (2010), pp. 975-982
[25]
C. Agustí, A. Torres.
Respuesta inflamatoria en la neumonía: ¿son útiles los glucocorticoides?.
Arch Bronconeumol, 39 (2003), pp. 143-145
[26]
P.E. Marik, S.M. Pastores, D. Annane, G.U. Meduri, C.L. Sprung, W. Arlt, et al.
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically adult patients: consensus statements from an international task force by the American College of Critical Care Medicine.
Crit Care Med, 36 (2008), pp. 1937-1949
[27]
R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, R. Jaeschke, et al.
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock 2008.
Crit Care Med, 36 (2008), pp. 296-327
Copyright © 2011. Sociedad Española de Neumología y Cirugía Torácica
